<DOC>
	<DOCNO>NCT01181791</DOCNO>
	<brief_summary>This application phase II clinical trial address possible active mechanism probiotic obtain preliminary efficacy safety data administration probiotic , Lactobacillus reuteri population premature infant . The hypothesis exogenous supplementation Lactobacillus reuteri premature infant lead clinical beneficial effect modify intestinal microbiota enhance intestinal immunological response .</brief_summary>
	<brief_title>Effects Lactobacillus Reuteri Premature Infants</brief_title>
	<detailed_description>The primary outcome `` day achieve full feed '' measure first month life Secondary outcome measure baseline ( intervention ) , 3 week intervention , intervention discontinue 6 month live</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Infant , Premature , Diseases</mesh_term>
	<criteria>Preterm newborn admit neonatal intensive care unit birth weight 7001500 g survive 3 day Chromosomal anomaly . Major congenital anomaly ( complex cardiac anomaly , congenital hydrocephalus , renal dysplasia ) Congenital ( e.g . jejunal atresia ) acquire ( e.g . GI perforation ) gastrointestinal pathology preclude oral feed and/or require major surgical medical intervention Parental refusal Prior enrollment conflict clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>probiotic</keyword>
	<keyword>premature infant</keyword>
	<keyword>feed tolerance</keyword>
</DOC>